Myriad and American College of Surgeons collaborate:
This article was originally published in Clinica
The American College of Surgeons and Myriad Genetic Laboratories are to collaborate on a long-term study into the outcomes of patients undergoing BRCA1 genetic analysis for breast and ovarian cancer susceptibility. The study will aim to discover which BRCA1 mutations are strongly penetrant as well as the likely clinical outcome after medical and surgical intervention.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.